Related Experiment Video
Updated: Aug 4, 2026
09:23
Isolation of Microvascular Endothelial Tubes from Mouse Resistance Arteries
Published on: November 25, 2013
Endothelin-I-mediated vasoconstriction: specific blockade by verapamil
N S Andrawis1, J Gilligan, D R Abernethy
1Program in Clinical Pharmacology, Brown University School of Medicine, Providence, RI.
Clinical Pharmacology and Therapeutics
|December 1, 1992
Summary
This study investigated how three vasodilators reverse endothelin-1 vasoconstriction. Verapamil, unlike isoproterenol and sodium nitroprusside, effectively reversed endothelin-1-induced vasoconstriction, indicating specific antagonism.
Area of Science:
- Cardiovascular Pharmacology
- Vascular Physiology
Background:
- Endothelin-1 is a potent vasoconstrictor implicated in various cardiovascular diseases.
- Understanding vasodilators that can counteract endothelin-1 effects is crucial for therapeutic development.
Purpose of the Study:
- To compare the capacity of three distinct vasodilators—isoproterenol, sodium nitroprusside, and verapamil—to reverse endothelin-1-mediated vasoconstriction.
- To elucidate the specific mechanisms by which these vasodilators interact with endothelin-1 pathways.
Main Methods:
- Brachial artery infusion and forearm strain-gauge plethysmography were employed in 11 healthy male subjects.
- The study assessed forearm vascular resistance (FVR) changes during infusions of endothelin-1 alone and in combination with isoproterenol, sodium nitroprusside, or verapamil.
Main Results:
- Endothelin-1 infusion significantly increased FVR (1.9-fold) in the control state.
- Isoproterenol and sodium nitroprusside reduced FVR but did not reverse the endothelin-1-induced increase.
- Verapamil significantly reduced FVR and reversed the endothelin-1-induced vasoconstriction, returning FVR to baseline levels (p < 0.05).
Conclusions:
- Verapamil acts as a specific antagonist to endothelin-1-mediated vasoconstriction.
- Isoproterenol and sodium nitroprusside, despite causing vasodilation, do not antagonize the vasoconstrictive effects of endothelin-1.
- These findings highlight verapamil's potential in managing conditions involving endothelin-1-induced vasoconstriction.
Related Concept Videos
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...